NICOX (EPA:COX) | Finanzwire

PRESS RELEASE

published on 06/06/2025 at 07:30, 10 months 24 days ago

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative
Nicox SA announces Ordinary and Extraordinary Shareholders' Meeting on June 27, 2025, appoints ad hoc representative. Details on agenda, proxy voting, and meeting participation

Shareholders' Meeting Proxy Voting Nicox SA Ad Hoc Representative Meeting Participation
BRIEF

published on 05/27/2025 at 07:35, 11 months 4 days ago

Nicox secures up to €3 million from Kowa to advance NCX 470

Ocular Hypertension Phase 3 Nicox NCX 470 Kowa
BRIEF

published on 05/14/2025 at 07:35, 11 months 17 days ago

Nicox Reports Findings from Whistler Phase 3b Glaucoma Trial

Glaucoma Nicox NCX 470 Whistler Phase 3b Intraocular Pressure
PRESS RELEASE

published on 05/14/2025 at 07:30, 11 months 17 days ago

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
Nicox announces positive results of Whistler Phase 3b glaucoma trial with NCX 470 showing efficacy in lowering intraocular pressure via dual mechanism action of nitric oxide and prostaglandin analogs. Safety profile consistent with previous trial

Nicox NCX 470 Glaucoma Trial Whistler Phase 3b Intraocular Pressure
BRIEF

published on 04/30/2025 at 07:35, 1 year ago

Nicox Reports Full Year 2024 Financials

Net Loss Cash Reserves Nicox Financial Results VYZULTA Revenue Sale NCX 470 Trials
PRESS RELEASE

published on 04/30/2025 at 07:30, 1 year ago

Nicox Provides Full Year 2024 Financial Results
Nicox reports €7.9 million revenue for 2024 with exceptional income of €13.7 million from VYZULTA transfer. Cash of €10.5 million and NCX 470 Phase 3 trial results expected in Q3 2025

Financial Results Revenue Nicox NCX 470 VYZULTA
BRIEF

published on 03/19/2025 at 07:35, 1 year 1 month ago

Nicox Completes Final Visit for NCX 470 Phase 3b Whistler Glaucoma Trial

Glaucoma Nicox Clinical Results NCX 470 Phase 3b Trial
PRESS RELEASE

published on 03/19/2025 at 07:30, 1 year 1 month ago

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
Nicox completes final patient visits in Phase 3b Whistler Glaucoma Trial for NCX 470, with results expected May 2025. Denali trial in progress, results planned for Q3 2025

Clinical Development Nicox NCX 470 Phase 3b Glaucoma Trial
BRIEF

published on 01/28/2025 at 07:35, 1 year 3 months ago

Nicox: Participation in Major Congresses in 2025

Investment Ophthalmology Congress Nicox NCX 470
PRESS RELEASE

published on 01/28/2025 at 07:30, 1 year 3 months ago

Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
Nicox to present at AGS 2025 Annual Meeting and attend key ophthalmology and financial conferences in H1 2025. Dr. Robert Fechtner to present NCX 470 analysis at AGS 2025

Conference Ophthalmology Nicox NCX 470 AGS 2025

Published on 05/01/2026 at 04:00, 2 hours 25 minutes ago

Jericho Energy Ventures Announces Short Delay in Filing of 2025 Annual Financial Statements
Published on 05/01/2026 at 03:25, 3 hours ago

McEwen Inc. and Golden Lake Exploration Inc. Announce Closing of Arrangement
Published on 05/01/2026 at 02:55, 3 hours 30 minutes ago

GLG Life Tech Corporation Reports 2025 Annual & Fourth Quarter Financial Results
Published on 05/01/2026 at 01:00, 5 hours 25 minutes ago

PPX Mining Announces Grant of Stock Options, Restricted Share Units and Deferred Share Units
Published on 05/01/2026 at 00:45, 5 hours 40 minutes ago

Inventus Announces Closing of $2.5 Million Non-Brokered Flow-Through Financing

View all ACCESSWIRE

Published on 04/30/2026 at 23:39, 6 hours 46 minutes ago

Anemoi International Ltd: Final Results For Year Ended 31 December 2025
Published on 04/30/2026 at 22:35, 7 hours 50 minutes ago

Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Published on 04/30/2026 at 22:04, 8 hours 21 minutes ago

Interim individual financial statements for the period ending on March 31, 2026 of Sirma Group Holding JSC
Published on 04/30/2026 at 19:00, 11 hours 24 minutes ago

DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 19:00, 11 hours 25 minutes ago

BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders

View all EQS

Published on 04/30/2026 at 20:00, 10 hours 24 minutes ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 11 hours 9 minutes ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 11 hours 25 minutes ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 12 hours 15 minutes ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 12 hours 25 minutes ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News